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Letter to the Editor
POSSIBILITY OF PRE-SELECTION OF PATIENTS FOR PROGNOSIS IN
ACUTE MYELOID LEUKAEMIA
SIR,-The new methods of chromosome
recognition offer possibilities of recognizing
different subgroups of AML based on their
chromosomal features. For this reason a
cytogenetic study has been undertaken of
the Manchester patients treated under the
MRC 6th AML trial protocol. The present
interim reportisabriefsummaryofchromoso-
mal findings in the first 73 patients.
Pre-treatment bone marrow biopsies from
the 73 patients could be grouped into three
categories: numerically and/or structurally
abnormalstemlinesrepresentingtheleukaemic
clone; normal stemline with abnormal side-
line(s); and normal stemline w%Nithout evidence
of abnormal sidelines.
The distribution of the patients and the
rate of remissions achieved was as follows:-
B.M. Remission
Abnormal stemline 26 cases (36%) 5 (19°0,)
Abnormal sideline(s) 12 cases (I6%) 1 (4°0)
Normal stemline 35 cases (48%) 20 (77°,h)
73 26
i.e. 57% of the normal stemlines and 165/0 of the
abnormal stemlines achieved remission.
Ofthe patients having expired at the time
of this summary, those witlh chromosome
abnormalities had an average survival of
68 days, while those with normal chromo-
somes survived on average 150 days.
The two main sub-populations, those w%ith
and those without chromosomeabnormalities,
have been displayed below on probability
paper, where % longer survival is plotted
against log survival in days. Since most
patients with chromosome abnormalities have
died, a straight line has been fitted for this
distribution. The T50 is estimated to be
47.5 days, with standard deviation and errors
displayed. The T50 for those with normal
ebromosomes will certainly be better than
250 days, since a number of these are still
alive.
The details of the chromosome study w-ill
be reported separately, and some aspects
only wNill be mentioned here. In the 26 ab-
normal stemlines, the chromosome numbers
varied from 43 to 50. Of these 19 lived for
less than 100 days, including all the 7 hypo-
diploids wTith autosomal loss, and 7 of the
hyperdiploids. Most of the hypodiploids
had complex changes, which was also a
feature of the short-lived pseudodiploids.
A striking feature of translocations was the
absence ofthe reciprocal translocation chrom-
osome, suggesting that the markers wxiere
derived from chromatid-exchange configur-
ations wN-hich had segregated. Ofthe 4 longer
lived hyperdiploids three were tris-C (No. 8)
and one with 50 chromosomes but with no
structural changes. In a previous trial, 8
remissions were achieved out of 32 patients,
6 of whom had normal chromosomes in all
samples. Two of these patients died after
442 and 969 days, and 4 are still alive after
754-877 days. It would appear that auto-
somal hypodiploids, mostly with structural
rearrangements, have a poor prognosis with
the therapy protocol applied. On the other
hand, simple addition of chromosomes, With-
out structural rearrangements, may inot do
any worse than those with normal findings.
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